Skip to main
MYGN

Myriad Genetics (MYGN) Stock Forecast & Price Target

Myriad Genetics (MYGN) Analyst Ratings

Based on 5 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 80%
Sell 20%
Strong Sell 0%

Bulls say

Myriad Genetics is facing some risks to downside like intense competition, share loss and price erosion, and FDA regulation of LDTs. However, with the company's strong portfolio of molecular tests and potential for growth through new product launches, the analyst remains positive about the company's outlook. The model updates show a steady increase in revenue and EPS over the next few years, indicating a strong financial future for Myriad Genetics. Additionally, GeneSight, one of the company's key tests, continues to show growth and expansion, providing a solid foundation for revenue growth. Lastly, the company is actively addressing any potential risks through cost-cutting measures and focusing on material ESG factors.

Bears say

Myriad Genetics is facing challenges that are structural and may not be temporary, with limited strategic interest in several business segments and a lack of line of sight to profitable growth that may require divestment of assets. Revenue growth is projected to be slow, and the company may struggle to reach its guidance for the year. Additionally, risks to the Medical and Life Science Tools sector may also impact the company, including reduced research and development budgets and increased dependence on volatile emerging markets.

Myriad Genetics (MYGN) has been analyzed by 5 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 80% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Myriad Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Myriad Genetics (MYGN) Forecast

Analysts have given Myriad Genetics (MYGN) a Hold based on their latest research and market trends.

According to 5 analysts, Myriad Genetics (MYGN) has a Hold consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Myriad Genetics (MYGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.